tetano
Editor, Senior Moderator
Virus Res
. 2024 Apr 19:199378.
doi: 10.1016/j.virusres.2024.199378. Online ahead of print. A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice
Zhenfei Wang[SUP] 1 [/SUP], Weiyang Sun[SUP] 2 [/SUP], Dongxu Li[SUP] 3 [/SUP], Yue Sun[SUP] 4 [/SUP], Menghan Zhu[SUP] 5 [/SUP], Wenqi Wang[SUP] 6 [/SUP], Yiming Zhang[SUP] 6 [/SUP], Entao Li[SUP] 2 [/SUP], Feihu Yan[SUP] 2 [/SUP], Tiecheng Wang[SUP] 2 [/SUP], Na Feng[SUP] 2 [/SUP], Songtao Yang[SUP] 2 [/SUP], Xianzhu Xia[SUP] 2 [/SUP], Yuwei Gao[SUP] 7 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to human health globally. It is crucial to develop a vaccine to reduce the effect of the virus on public health, economy, and society and regulate the transmission of SARS-CoV-2. Influenza B virus (IBV) can be used as a vector that does not rely on the current circulating influenza A strains. In this study, we constructed an IBV-based vector vaccine by inserting a receptor-binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell-mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This novel IBV-based vaccine offers a novel approach for controlling the SARS-CoV-2 pandemic.
Keywords: SARS-CoV-2; influenza virus-vector vaccine; intranasal vaccination; mice; spike RBD.
. 2024 Apr 19:199378.
doi: 10.1016/j.virusres.2024.199378. Online ahead of print. A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice
Zhenfei Wang[SUP] 1 [/SUP], Weiyang Sun[SUP] 2 [/SUP], Dongxu Li[SUP] 3 [/SUP], Yue Sun[SUP] 4 [/SUP], Menghan Zhu[SUP] 5 [/SUP], Wenqi Wang[SUP] 6 [/SUP], Yiming Zhang[SUP] 6 [/SUP], Entao Li[SUP] 2 [/SUP], Feihu Yan[SUP] 2 [/SUP], Tiecheng Wang[SUP] 2 [/SUP], Na Feng[SUP] 2 [/SUP], Songtao Yang[SUP] 2 [/SUP], Xianzhu Xia[SUP] 2 [/SUP], Yuwei Gao[SUP] 7 [/SUP]
Affiliations
- PMID: 38643857
- DOI: 10.1016/j.virusres.2024.199378
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to human health globally. It is crucial to develop a vaccine to reduce the effect of the virus on public health, economy, and society and regulate the transmission of SARS-CoV-2. Influenza B virus (IBV) can be used as a vector that does not rely on the current circulating influenza A strains. In this study, we constructed an IBV-based vector vaccine by inserting a receptor-binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell-mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This novel IBV-based vaccine offers a novel approach for controlling the SARS-CoV-2 pandemic.
Keywords: SARS-CoV-2; influenza virus-vector vaccine; intranasal vaccination; mice; spike RBD.